» Articles » PMID: 10222510

Genetic Testing and Informed Consent

Overview
Specialties Nursing
Oncology
Date 1999 May 1
PMID 10222510
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To discuss unique issues related to cancer predisposition genetic testing and informed consent.

Data Sources: Published professional articles, review articles, research articles, clinical practice, position statements, websites, and textbooks.

Conclusions: The discovery of germline mutations that confer a predisposition for the development of cancer will continue. The provision of adequate information is central to the process of genetic counseling and testing so that individuals may give informed consent and make choices appropriate to their own specific circumstances.

Implications For Nursing Practice: The use of genetic information for the management of cancer will impact the practice of all oncology nurses in the coming years. Knowledge of genes that predispose for cancer and standards that delineate essential components of quality care during the informed consent process is vital.

Citing Articles

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.

Pereira L, Haidar C, Haga S, Cisler A, Hall A, Shukla S Front Pharmacol. 2024; 15:1355412.

PMID: 38410134 PMC: 10895424. DOI: 10.3389/fphar.2024.1355412.


A review of consent practices and perspectives for pharmacogenetic testing.

Haga S, Mills R Pharmacogenomics. 2016; 17(14):1595-605.

PMID: 27533720 PMC: 5220438. DOI: 10.2217/pgs-2016-0039.